{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-006796","form_type":"8-K","ticker":"ITGR","cik":"0001114483","company_name":"Integer Holdings Corp","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.652166+00:00","generated_at":"2026-06-22T23:32:48.682320+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Integer Q3 sales up 12% to $343M; GAAP net income down 27% to $16M","bullets":["Sales increased 12% to $343M; GAAP EPS $0.48 vs $0.66 prior year; adjusted EPS $0.95 vs $1.05.","Cardio & Vascular sales +14%; Cardiac Rhythm Management +8%; Advanced Surgical +17%; Electrochem +24%.","2022 outlook: GAAP sales $1.35-1.38B, adj. EBITDA $244-260M, adj. EPS $3.57-3.97; organic growth 4-6%.","Total debt rose $111M to $939M due to Aran Biomedical acquisition for $129M; leverage ratio 3.8x.","CEO expects 2023 revenue growth of 7-9% with margin expansion; supply chain delays to be recovered in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-006796","json":"https://secwatch.observer/filing/0001171843-22-006796.json","markdown":"https://secwatch.observer/filing/0001171843-22-006796.md","text":"https://secwatch.observer/filing/0001171843-22-006796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114483/000117184322006796/0001171843-22-006796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114483/000117184322006796/f8k_102622.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:32:48.682320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a183e66a9b224d7fbc8c2ad8cbcaa0443568c17c","claim":"Integer Holdings Corp reported three months ended September 30, 2022 results: revenue $343 million, net income $16 million, EPS $0.48 per share. Guidance reaffirmed.","evidence_excerpt":"today announced results for the three months ended September 30, 2022. Third Quarter 2022 Highlights (compared to Third Quarter 2021, except as noted) Sales increased 12% to $343 million. GAAP net income decreased $6 million to $16 million, a decrease of 27%. Non-GAAP adjusted net income decreased $3 million to $32 million, a decrease of 9%. GAAP operating income","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1114483/000117184322006796/0001171843-22-006796-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Revenue","value":"$343 million"},{"label":"Net income","value":"$16 million"},{"label":"EPS","value":"$0.48 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}